Fluorouracil, Cisplatin, Leucovorin Calcium, and Cetuximab in Treating Patients With Adenocarcinoma of the Stomach or Gastroesophageal Junction
NCT ID: NCT01360086
Last Updated: 2016-05-30
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
65 participants
INTERVENTIONAL
2011-06-30
2013-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
PURPOSE: This phase II trial is studying the side effects of giving fluorouracil, cisplatin, and leucovorin calcium together with cetuximab and to see how well they work in treating patients with adenocarcinoma of the stomach or gastroesophageal junction.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Primary
* To evaluate the objective response rate according to RECIST V1.1 criteria in patients with adenocarcinoma of the stomach or gastroesophageal junction treated with neoadjuvant chemotherapy comprising fluorouracil, cisplatin, leucovorin calcium, and cetuximab followed by surgery and adjuvant chemotherapy.
* To determine the non-toxicity rate in these patients.
Secondary
* To determine the rate of macroscopically and microscopically complete surgical resection (R0).
* To determine the overall tolerance in patients treated with this regimen.
* To determine post-operative mortality and morbidity in these patients.
* To determine the rate of recurrence at 1 and 2 years in these patients.
* To determine recurrence-free survival at 3 years in these patients.
* To determine disease-free survival at 3 years in these patients.
* To determine overall survival at 3 years in these patients.
* To determine quality of life using EORTC QLC-C30 and STO-22 questionnaires.
* To determine the correlation between the response rate and the degree of skin toxicity.
OUTLINE: This is a multicenter study.
* Neoadjuvant therapy and surgery: Patients receive leucovorin calcium IV over 2 hours, cisplatin IV, fluorouracil IV continuously over 46 hours, and cetuximab IV over 1-2 hours on day 1. Treatment repeats every 2 weeks for 6 courses in the absence of disease progression or unacceptable toxicity. Within 3-4 weeks after completing neoadjuvant chemotherapy, patients undergo surgery.
* Adjuvant therapy: Within 4-8 weeks after completing neoadjuvant chemotherapy, patients receive leucovorin calcium, cisplatin, fluorouracil, and cetuximab as in neoadjuvant therapy. Treatment repeats every 2 weeks for 6 courses in the absence of disease progression or unacceptable toxicity.
Patients complete quality-of-life questionnaires (QLC-C30 and STO-22) periodically. Blood and tissue samples are collected periodically for correlative and translational studies.
After completing study therapy, patients are followed up every 4 months for 2 years and then every 6 months for 1 year.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Perioperative CT with 5FU-Cisplatine-Cetuximab
6 cycles of intravenous Cetuximab (500mg/m²), Cisplatine (50mg/m²) and LV5FU2s (folinic acid 400mg/m², 5FU bolus 400mg/m², and continuous infusion of 5FU 2400mg/m²) every 2 weeks. Surgery was planned 3-4 weeks after the end of neaodjuvant CT and postoperative CT, with the same regimen, planned for 6-8 weeks after surgery.
cetuximab
6 cycles of intravenous Cetuximab (500mg/m²),
cisplatin
Cisplatine (50mg/m²)
fluorouracil
LV5FU2s (folinic acid 400mg/m², 5FU bolus 400mg/m², and continuous infusion of 5FU 2400mg/m²) every 2 weeks
leucovorin calcium
adjuvant therapy
neoadjuvant therapy
quality-of-life assessment
therapeutic conventional surgery
Surgery was planned 3-4 weeks after the end of neaodjuvant CT
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
cetuximab
6 cycles of intravenous Cetuximab (500mg/m²),
cisplatin
Cisplatine (50mg/m²)
fluorouracil
LV5FU2s (folinic acid 400mg/m², 5FU bolus 400mg/m², and continuous infusion of 5FU 2400mg/m²) every 2 weeks
leucovorin calcium
adjuvant therapy
neoadjuvant therapy
quality-of-life assessment
therapeutic conventional surgery
Surgery was planned 3-4 weeks after the end of neaodjuvant CT
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Histologically confirmed adenocarcinoma of the stomach or gastroesophageal junction
* Stage IB, II, or III disease according to TNM classification OR type I, II, or III disease according to Siewert classification
* TNM: T1N1-3, T2N0-3, T3N0-3, or T4N0-3 (no T1N0 or M1)
* Disease considered operable with curative intent
* No gastric scirrhous carcinoma (linitis plastica)
* Forms with independent cells are not considered linitis
* Measurable disease according to RECIST V1.1
* No planned esophagectomy without thoracotomy in patients with adenocarcinoma of the gastroesophageal junction type I
PATIENT CHARACTERISTICS:
* WHO performance status 0-2
* Polynuclear neutrophil count ≥ 1,500/mm³
* Platelet count ≥ 100,000/mm³
* Creatinine clearance \> 50 mL/min
* Bilirubin \< 1.5 times normal
* Serum albumin \> 30 g/L
* Prothrombin time ≥ 80%
* FEV1 \> 1 L in case of thoracotomy
* Not pregnant or nursing
* Negative pregnancy test
* Fertile patients must use effective contraception
* No known cirrhosis
* No other progressive condition that has not been stabilized including the following:
* Hepatic failure
* Renal failure
* Respiratory failure
* NYHA class III-IV congestive heart failure
* Unstable angina
* Myocardial infarction in the past 6 months
* Significant arrhythmias in the past 12 months
* No recent weight loss exceeding 15%
* No interstitial pneumonia
* No other malignant tumor within the past 5 years except for basal cell skin carcinoma or cancer in situ of the cervix
* No psychological, familial, or geographical reasons that will preclude the patient being monitored regularly
* No persons deprived of liberty or under guardianship (Disability Act)
PRIOR CONCURRENT THERAPY:
* See Disease Characteristics
* No prior chemotherapy or radiotherapy for gastric cancer
* No other concurrent anticancer treatment, immunotherapy, or hormone therapy
* No prior abdominal or thoracic radiotherapy
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Federation Francophone de Cancerologie Digestive
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Christophe Mariette, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Centre Hospitalier Regional et Universitaire de Lille
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Centre Hospitalier Regional et Universitaire de Lille
Lille, , France
CHU - Robert Debre
Reims, , France
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Mariette C, Dahan L, Mornex F, Maillard E, Thomas PA, Meunier B, Boige V, Pezet D, Robb WB, Le Brun-Ly V, Bosset JF, Mabrut JY, Triboulet JP, Bedenne L, Seitz JF. Surgery alone versus chemoradiotherapy followed by surgery for stage I and II esophageal cancer: final analysis of randomized controlled phase III trial FFCD 9901. J Clin Oncol. 2014 Aug 10;32(23):2416-22. doi: 10.1200/JCO.2013.53.6532. Epub 2014 Jun 30.
Gronnier C, Mariette C, Lepage C, Monterymard C, Jary M, Ferru A, Baconnier M, Adhoute X, Tavan D, Perrier H, Guerin-Meyer V, Lecaille C, Bonichon-Lamichhane N, Pillon D, Cojocarasu O, Egreteau J, D'journo XB, Dahan L, Locher C, Texereau P, Collet D, Michel P, Ben Abdelghani M, Guimbaud R, Muller M, Bouche O, Piessen G. Perioperative Cetuximab with Cisplatin and 5-Fluorouracil in Esogastric Adenocarcinoma: A Phase II Study. Cancers (Basel). 2023 Apr 6;15(7):2188. doi: 10.3390/cancers15072188.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
FFCD-0901
Identifier Type: -
Identifier Source: secondary_id
EU-21111
Identifier Type: -
Identifier Source: secondary_id
EUDRACT-2010-023115-33
Identifier Type: -
Identifier Source: secondary_id
MERCK-FFCD-0901
Identifier Type: -
Identifier Source: secondary_id
CDR0000699219
Identifier Type: -
Identifier Source: org_study_id